Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

PHASE1RecruitingINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

October 10, 2018

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Colorectal AdenocarcinomaEwing Sarcoma
Interventions
DRUG

INBRX-109

Tetravalent DR5 Agonist Antibody

DRUG

Carboplatin

Chemotherapy

DRUG

Cisplatin

Chemotherapy

DRUG

Pemetrexed

Chemotherapy

DRUG

5-fluorouracil

Chemotherapy

DRUG

Irinotecan

Chemotherapy

DRUG

Temozolomide

Chemotherapy

Trial Locations (34)

10021

RECRUITING

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

10060

RECRUITING

La Fondazione e l'Istituto di Candiolo, Candiolo

19104

RECRUITING

Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia

19106

RECRUITING

University of Pennsylvania Abramson Cancer Center, Philadelphia

20123

NOT_YET_RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

20892

NOT_YET_RECRUITING

Center for Cancer Research at NCI, Bethesda

22031

RECRUITING

NEXT Oncology - Virginia, Fairfax

22903

NOT_YET_RECRUITING

University of Virginia, Charlottesville

28040

RECRUITING

Hospital Clinico San Carlos, Madrid

30322

RECRUITING

Emory University - Winship Cancer Institute, Atlanta

37232

RECRUITING

Vanderbilt University School of Medicine, Nashville

44195

RECRUITING

Cleveland Clinic, Cleveland

48109

RECRUITING

University of Michigan, Ann Arbor

49546

RECRUITING

START Midwest Michigan, PC, Grand Rapids

60637

COMPLETED

The University of Chicago, Chicago

69008

RECRUITING

Centre Leon Berard, Lyon

77030

RECRUITING

UT MD Anderson Cancer Center, Houston

78229

COMPLETED

NEXT Oncology, San Antonio

80045

RECRUITING

University of Colorado Hospital, Aurora

85258

COMPLETED

HonorHealth Research Institute, Scottsdale

90067

RECRUITING

Valkyrie Clinical Trials, Los Angeles

90212

RECRUITING

Precision NextGen Oncology and Research, Beverly Hills

90403

RECRUITING

Sarcoma Oncology Center, Santa Monica

91010

RECRUITING

City of Hope, Duarte

92093

RECRUITING

University of California, San Diego (UCSD) - Moores Cancer Center, San Diego

94110

RECRUITING

University of California, San Francisco (UCSF), San Francisco

94805

RECRUITING

Gustave Roussy, Villejuif

97239

RECRUITING

Oregon Health & Science University, Portland

08035

NOT_YET_RECRUITING

Hospital Universitario Vall d'Hebron, Barcelona

08041

RECRUITING

Hospital de la Santa Creu i Sant Pau, Barcelona

EC4V 3BJ

NOT_YET_RECRUITING

Great North Children's Hospital, London

NW1 2PG

RECRUITING

University College London Hospital, London

SW3 6JJ

NOT_YET_RECRUITING

The Royal Marsden NHS Foundation Trust, London

M13 9WL

NOT_YET_RECRUITING

Royal Manchester Children's Hospital, Manchester

Sponsors
All Listed Sponsors
lead

Inhibrx Biosciences, Inc

INDUSTRY

NCT03715933 - Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Biotech Hunter | Biotech Hunter